Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery
NCT ID: NCT05429749
Last Updated: 2022-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
264 participants
INTERVENTIONAL
2020-07-30
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia
NCT05911438
The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy
NCT06442111
Efficacy of Ferric Carboxymaltose With or Without EPO Reducing Red-cell Transfusion Packs in Hip Fracture Perioperative Period
NCT01154491
Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma
NCT05292001
Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery
NCT01345968
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ferinject group
This group of hip fracture patients are treated with intravenous Ferinject between the admission and the surgery day.
Ferinject
Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
Control group
This group of hip fracture patients are treated with normal saline as a control group.
Normal saline
Normal saline 250ml is administered between the admission day and the surgery day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ferinject
Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
Normal saline
Normal saline 250ml is administered between the admission day and the surgery day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Iron deficiency anemia (Hb\<12 in women, Hb\<13 in men)
* Iron deficiency (Serum ferritin \<100ug/L or transferrin saturation\<20%)
* Who understands this clinical trial and volunteers and agrees to this trial
Exclusion Criteria
* Hb\<7 or someone who has acute symptom of anemia(tachycardia, dyspnea, or dizziness)
* High energy trauma
* Preoperative delirium
* MMSE\<10
* Underlying disease which involves cognitive dysfunction (e.g. neurovascular diseases, acute myocardial infarction, pulmonary embolism)
* Those who are inappropriate to participate in the clinical trial assessed by the investigators
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Seoul National University Bundang Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Young-Kyun Lee
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Bundang Hospital
Seongnam, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ferinject
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.